On the clinical pharmacology of talinolol, a new beta 1-adrenoceptor blocking agent.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D002415:Cats; D004285:Dogs; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D006168:Guinea Pigs; D006207:Half-Life; D006329:Heart Conduction System / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D007700:Kinetics; D009119:Muscle Contraction / Q000187:drug effects; D010671:Phenylurea Compounds / Q000494:pharmacology; D011412:Propanolamines / Q000494:pharmacology*
D000319:Adrenergic beta-Antagonists; D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D010671:Phenylurea Compounds; D011412:Propanolamines; C011550:talinolol